Arginine deprivation therapy for malignant melanoma

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue 1, 2012, Pages 11-19

  Yoon, Jung Ki ^a,b   Frankel, Arthur E ^c   Feun, Lynn G ^d   Ekmekcioglu, Suhendan ^a   Kim, Kevin B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hwasung Public Health Center   (South Korea)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Arginine deprivation; Argininosuccinate synthetase; Melanoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; ARGINASE; ARGININE; ARGININE DECARBOXYLASE; ARGININE DEIMINASE; CANAVANINE; CISPLATIN; COBALT SUBSTITUTED PEGYLATED RECOMBINANT HUMAN ARGINASE; MACROGOL; PEGYLATED RECOMBINANT HUMAN ARGINASE; RECOMBINANT HUMAN ARGINASE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UREA;

ADVANCED CANCER; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARGININE DEPRIVATION THERAPY; BILIRUBIN BLOOD LEVEL; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; DIARRHEA; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; HUMAN; HYPERURICEMIA; HYPOTENSION; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; KIDNEY CARCINOMA; LIVER CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; MELANOMA; METASTATIC MELANOMA; NONHUMAN; OSTEOSARCOMA; PLEURA MESOTHELIOMA; POTASSIUM BLOOD LEVEL; PROSTATE CANCER; PROTEIN DEGRADATION; PRURITUS; REVIEW; SIDE EFFECT; SKIN IRRITATION; SODIUM BLOOD LEVEL; SOLID TUMOR; T CELL LEUKEMIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UREA CYCLE;

EID: 84871890551     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S37350     Document Type: Review

References (50)

1. Weinstock MA. Epidemiology, etiology, and control of melanoma. Med Health R I. 2001;84(7):234-236.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
4. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998-1012.
5. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2in the treatment of 652 cancer patients. Ann Surg. 1989;210(4):474-484.
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
8. Flaherty KT, McArthur G. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer. 2010;116(21):4902-4913.
9. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
10. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma [abstract]. J Clin Oncol. 2011;29:8509.
11. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
12. Morris SM Jr. Arginine: beyond protein. Am J Clin Nutr. 2006;83(2):508S-512S.
13. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28(2):97-113.
14. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer. 2004;100(4):826-833.
15. Savoca KV, Davis FF, van Es T, McCoy JR, Placzuk NC. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia. Cancer Biochem Biophys. 1984;7(3):261-268.
16. Cheng PN, Lam TL, Lam WM, et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67(1):309-317.
17. Agrawal V, Woo JH, Mauldin JP, et al. Cytotoxicity of human recombinant arginase I (Co)-PEG5000in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anticancer Drugs. 2012;23(1):51-64.
18. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med. 2010;10(4):405-412.
19. Mauldin JP, Zeinali I, Kleypas K, et al. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Transl Oncol. 2012;5(1):26-31.
20. Das K, Butler GH, Kwiatkowski V, Clark AD Jr, Yadav P, Arnold E. Crystal structures of arginine deiminase with covalent reaction intermediates; implications for catalytic mechanism. Structure. 2004;12(4):657-667.
21. Takaku H, Matsumoto M, Misawa S, Miyazaki K. Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism. Jpn J Cancer Res. 1995;86(9):840-846.
22. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 2002;62(19):5443-5450.
23. Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release. 2002;80(1-3):259-271.
24. Takaku H, Takase M, Abe S, Hayashi H, Miyazaki K. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int J Cancer. 1992;51(2):244-249.
25. Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs. 2006;15(7):815-822.
26. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget. 2010;1(4):246-251.
27. Lam TL, Wong GK, Chow HY, et al. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res. 2011;24(2):366-376.
28. Stone EM, Glazer ES, Chantranupong L, et al. Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. ACS Chem Biol. 2010;5(3):333-342.
29. Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011;4(3):138-146.
30. Feun LG, You M, Wu C, et al. Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM) [abstract]. J Clin Oncol. 2010;28(Suppl 15):8528.
31. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther. 2009;8(12):3223-3233.
32. Feun L, You M, Wu CJ, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des. 2008;14(11):1049-1057.
33. You M, Savaraj N, Wu CJ, et al. Enhancing arginine deprivation therapy in melanoma by combining with cisplatin. Paper presented at: 101st Annual Meeting of the American Association of Cancer Research; April 17-21, 2010; Washington, DC.
34. You M, Savaraj N, Wangpaichitr M, et al. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun. 2010;394(3):760-766.
35. Vynnytska BO, Mayevska OM, Kurlishchuk YV, Bobak YP, Stasyk OV. Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells. Anticancer Drugs. 2011;22(2):148-157.
36. Vynnytska-Myronovska B, Bobak Y, Garbe Y, Dittfeld C, Stasyk OV, Kunz-Schughart LA. Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation. Int J Cancer. 2012;130(9):2164-2175.
37. Szlosarek PW, Klabatsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res. 2006;12(23):7126-7131.
38. Yoon CY, Shim YJ, Kim EH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer. 2007;120(4):897-905.
39. Kim RH, Coates JM, Bowles TL, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 2009;69(2):700-708.
40. Noh EJ, Kang SW, Shin YJ, et al. Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. Int J Cancer. 2004;112(3):502-508.
41. Kobayashi E, Masuda M, Nakayama R, et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther. 2010;9(3):535-544.
42. Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA. Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology. 2003;50(53):1214-1216.
43. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol. 2004;22(10):1815-1822.
44. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol. 2005;23(30):7660-7668.
45. Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev. 1998;17(1):107-118.
46. Vallance P, Leiper J. Blocking NO synthesis: how, where and why? Nat Rev Drug Discov. 2002;1(12):939-950.
47. Cooke JP. NO and angiogenesis. Atheroscler Suppl. 2003;4(4):53-60.
48. Glazer ES, Piccirillo M, Albino V, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol. 2010;28(13):2220-2226.
49. Yang TS, Lu SN, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer. 2010;103(7):954-960.
50. Yau CC, Chan P, Pang R, et al. A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma [abstract]. J Clin Oncol. 2010;28:e13503.